1. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
- Author
-
Jung-Jr Ye, Huang-Shen Lin, Ming-Hsun Lee, Chien-Chang Yang, Chun-Fu Yeh, Yen-Mu Wu, Ching-Tai Huang, and Po-Yen Huang
- Subjects
0301 basic medicine ,Acinetobacter baumannii ,Adult ,Male ,medicine.medical_specialty ,030106 microbiology ,Taiwan ,Minocycline ,Tigecycline ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Ampicillin ,Internal medicine ,Drug Resistance, Multiple, Bacterial ,medicine ,Pneumonia, Bacterial ,Humans ,030212 general & internal medicine ,Acinetobacter calcoaceticus ,Aged ,Retrospective Studies ,Aged, 80 and over ,biology ,business.industry ,Mortality rate ,Sulbactam ,Acinetobacter ,Middle Aged ,biology.organism_classification ,medicine.disease ,Surgery ,Anti-Bacterial Agents ,Pneumonia ,Treatment Outcome ,Infectious Diseases ,Carbapenems ,Drug Therapy, Combination ,Female ,business ,medicine.drug ,Research Article ,Acinetobacter Infections - Abstract
Background The treatment options for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (MDR Acb) complex are limited, and the optimal treatment has not been established. Methods To compare the efficacy of tigecycline-based with sulbactam (or ampicillin/sulbactam)-based therapy for pneumonia involving MDR Acb complex, we conducted a retrospective study comparing 84 tigecycline-treated adult patients during the period August 2007 to March 2010 with 84 sulbactam or ampicillin/sulbactam-treated adult patients during the period September 2004 to July 2007. Both groups had the matched Acute Physiology and Chronic Health Evaluation (APACHE) II score and received treatment for at least 7 days. Results The mean APACHE II score was 20.1 for both groups. More patients in sulbactam group had ventilator use (89.3 % versus 69.0 %), bilateral pneumonia (79.8 % versus 60.7 %) and combination therapy (84.5 % versus 53.6 %), particularly with carbapenems (71.4 % versus 6.0 %), while more patients in tigecycline group had delayed treatment (41.7 % versus 26.2 %) (P
- Full Text
- View/download PDF